Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following ChemoradiotherapyBusiness Wire • 07/30/21
Bristol Myers Squibb (BMY) CEO Giovanni Caforio on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 07/28/21
Bristol Myers Q2 Earnings Slightly Ahead Of Estimates, Trims FY21 GAAP EPS GuidanceBenzinga • 07/28/21
Bristol Myers swings to profit to beat second-quarter estimates as Opdivo returns to growthMarket Watch • 07/28/21
Bristol Myers Squibb (BMY) Stock Moves -0.19%: What You Should KnowZacks Investment Research • 07/16/21
Bristol Myers says late-stage trial of head and neck cancer treatment failed to meet main goalsMarket Watch • 07/16/21